ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Pril-series Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-22Z16995
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Pril series Drugs Market Research Report 2024
BUY CHAPTERS

Global Pril-series Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-22Z16995
Report
November 2025
Pages:127
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Servier
Sanofi
Novartis
Bristol Myers Squibb Company
Pfizer Inc
Huahai Pharmaceutical
Shenzhen Salubris Pharmaceuticals
TAD Pharma
Organon Pharma
Kunshan Rotam Reddy Pharmaceutical

Pril-series Drugs Market

The global Pril-series Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Pril-series drugs are one of the commonly used antihypertensive drugs in clinical practice, ending with "Pril", such as perindopril and enalapril. Pril-series drugs are called Angiotensin-converting enzyme (ACE) inhibitors, are medicines that help relax the veins and arteries to lower blood pressure. ACE inhibitors prevent an enzyme in the body from making angiotensin 2, a substance that narrows blood vessels. This narrowing can cause high blood pressure and forces the heart to work harder.
From a downstream perspective, Hospital Pharmaty accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Pril-series Drugs leading manufacturers including Servier, Sanofi, Novartis, Bristol-Myers Squibb Company, Pfizer, TAD Pharma, Organon Pharma, Huahai Pharmaceutical, Kunshan Rotam Reddy Pharmaceutical, Shenzhen Salubris Pharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Servier leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Pril-series Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Pril-series Drugs Market Report

Report Metric Details
Report Name Pril-series Drugs Market
Segment by Type
  • Enalapril
  • Lisinopril
  • Captopril
  • Ramipril
  • Perindopril
  • Others
Segment by Application
  • Hospital Pharmaty
  • Retail Pharmacy
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Servier, Sanofi, Novartis, Bristol-Myers Squibb Company, Pfizer, TAD Pharma, Organon Pharma, Huahai Pharmaceutical, Kunshan Rotam Reddy Pharmaceutical, Shenzhen Salubris Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Pril-series Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Pril-series Drugs Market report?

Ans: The main players in the Pril-series Drugs Market are Servier, Sanofi, Novartis, Bristol-Myers Squibb Company, Pfizer, TAD Pharma, Organon Pharma, Huahai Pharmaceutical, Kunshan Rotam Reddy Pharmaceutical, Shenzhen Salubris Pharmaceuticals

What are the Application segmentation covered in the Pril-series Drugs Market report?

Ans: The Applications covered in the Pril-series Drugs Market report are Hospital Pharmaty, Retail Pharmacy

What are the Type segmentation covered in the Pril-series Drugs Market report?

Ans: The Types covered in the Pril-series Drugs Market report are Enalapril, Lisinopril, Captopril, Ramipril, Perindopril, Others

1 Study Coverage
1.1 Introduction to Pril-series Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pril-series Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Enalapril
1.2.3 Lisinopril
1.2.4 Captopril
1.2.5 Ramipril
1.2.6 Perindopril
1.2.7 Others
1.3 Market Segmentation by Application
1.3.1 Global Pril-series Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmaty
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pril-series Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Pril-series Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Pril-series Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Pril-series Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Enalapril Market Size by Players
3.3.2 Lisinopril Market Size by Players
3.3.3 Captopril Market Size by Players
3.3.4 Ramipril Market Size by Players
3.3.5 Perindopril Market Size by Players
3.3.6 Others Market Size by Players
3.4 Global Pril-series Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Pril-series Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Pril-series Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Pril-series Drugs Market Size by Type (2020-2031)
6.4 North America Pril-series Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Pril-series Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Pril-series Drugs Market Size by Type (2020-2031)
7.4 Europe Pril-series Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Pril-series Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Pril-series Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Pril-series Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Pril-series Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Pril-series Drugs Market Size by Type (2020-2031)
9.4 Central and South America Pril-series Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Pril-series Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Pril-series Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Pril-series Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Pril-series Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Servier
11.1.1 Servier Corporation Information
11.1.2 Servier Business Overview
11.1.3 Servier Pril-series Drugs Product Features and Attributes
11.1.4 Servier Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.1.5 Servier Pril-series Drugs Revenue by Product in 2024
11.1.6 Servier Pril-series Drugs Revenue by Application in 2024
11.1.7 Servier Pril-series Drugs Revenue by Geographic Area in 2024
11.1.8 Servier Pril-series Drugs SWOT Analysis
11.1.9 Servier Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Pril-series Drugs Product Features and Attributes
11.2.4 Sanofi Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Pril-series Drugs Revenue by Product in 2024
11.2.6 Sanofi Pril-series Drugs Revenue by Application in 2024
11.2.7 Sanofi Pril-series Drugs Revenue by Geographic Area in 2024
11.2.8 Sanofi Pril-series Drugs SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Business Overview
11.3.3 Novartis Pril-series Drugs Product Features and Attributes
11.3.4 Novartis Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.3.5 Novartis Pril-series Drugs Revenue by Product in 2024
11.3.6 Novartis Pril-series Drugs Revenue by Application in 2024
11.3.7 Novartis Pril-series Drugs Revenue by Geographic Area in 2024
11.3.8 Novartis Pril-series Drugs SWOT Analysis
11.3.9 Novartis Recent Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Corporation Information
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Pril-series Drugs Product Features and Attributes
11.4.4 Bristol-Myers Squibb Company Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.4.5 Bristol-Myers Squibb Company Pril-series Drugs Revenue by Product in 2024
11.4.6 Bristol-Myers Squibb Company Pril-series Drugs Revenue by Application in 2024
11.4.7 Bristol-Myers Squibb Company Pril-series Drugs Revenue by Geographic Area in 2024
11.4.8 Bristol-Myers Squibb Company Pril-series Drugs SWOT Analysis
11.4.9 Bristol-Myers Squibb Company Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Pril-series Drugs Product Features and Attributes
11.5.4 Pfizer Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Pril-series Drugs Revenue by Product in 2024
11.5.6 Pfizer Pril-series Drugs Revenue by Application in 2024
11.5.7 Pfizer Pril-series Drugs Revenue by Geographic Area in 2024
11.5.8 Pfizer Pril-series Drugs SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 TAD Pharma
11.6.1 TAD Pharma Corporation Information
11.6.2 TAD Pharma Business Overview
11.6.3 TAD Pharma Pril-series Drugs Product Features and Attributes
11.6.4 TAD Pharma Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.6.5 TAD Pharma Recent Developments
11.7 Organon Pharma
11.7.1 Organon Pharma Corporation Information
11.7.2 Organon Pharma Business Overview
11.7.3 Organon Pharma Pril-series Drugs Product Features and Attributes
11.7.4 Organon Pharma Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.7.5 Organon Pharma Recent Developments
11.8 Huahai Pharmaceutical
11.8.1 Huahai Pharmaceutical Corporation Information
11.8.2 Huahai Pharmaceutical Business Overview
11.8.3 Huahai Pharmaceutical Pril-series Drugs Product Features and Attributes
11.8.4 Huahai Pharmaceutical Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.8.5 Huahai Pharmaceutical Recent Developments
11.9 Kunshan Rotam Reddy Pharmaceutical
11.9.1 Kunshan Rotam Reddy Pharmaceutical Corporation Information
11.9.2 Kunshan Rotam Reddy Pharmaceutical Business Overview
11.9.3 Kunshan Rotam Reddy Pharmaceutical Pril-series Drugs Product Features and Attributes
11.9.4 Kunshan Rotam Reddy Pharmaceutical Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.9.5 Kunshan Rotam Reddy Pharmaceutical Recent Developments
11.10 Shenzhen Salubris Pharmaceuticals
11.10.1 Shenzhen Salubris Pharmaceuticals Corporation Information
11.10.2 Shenzhen Salubris Pharmaceuticals Business Overview
11.10.3 Shenzhen Salubris Pharmaceuticals Pril-series Drugs Product Features and Attributes
11.10.4 Shenzhen Salubris Pharmaceuticals Pril-series Drugs Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Pril-series DrugsIndustry Chain Analysis
12.1 Pril-series Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pril-series Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pril-series Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Servier
Sanofi
Novartis
Bristol Myers Squibb Company
Pfizer Inc
Huahai Pharmaceutical
Shenzhen Salubris Pharmaceuticals
TAD Pharma
Organon Pharma
Kunshan Rotam Reddy Pharmaceutical
List of Tables
 Table 1. Global Pril-series Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Pril-series Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Pril-series Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Pril-series Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Pril-series Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Pril-series Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Pril-series Drugs Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Pril-series Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pril-series Drugs as of 2024)
 Table 11. Global Pril-series Drugs Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Pril-series Drugs Companies Headquarters
 Table 13. Global Pril-series Drugs Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Pril-series Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Pril-series Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Pril-series Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Pril-series Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Pril-series Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Pril-series Drugs Growth Accelerators and Market Barriers
 Table 25. North America Pril-series Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Pril-series Drugs Growth Accelerators and Market Barriers
 Table 27. Europe Pril-series Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Pril-series Drugs Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Pril-series Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Pril-series Drugs Investment Opportunities and Key Challenges
 Table 31. Central and South America Pril-series Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Pril-series Drugs Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Pril-series Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Servier Corporation Information
 Table 35. Servier Description and Major Businesses
 Table 36. Servier Product Features and Attributes
 Table 37. Servier Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Servier Revenue Proportion by Product in 2024
 Table 39. Servier Revenue Proportion by Application in 2024
 Table 40. Servier Revenue Proportion by Geographic Area in 2024
 Table 41. Servier Pril-series Drugs SWOT Analysis
 Table 42. Servier Recent Developments
 Table 43. Sanofi Corporation Information
 Table 44. Sanofi Description and Major Businesses
 Table 45. Sanofi Product Features and Attributes
 Table 46. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Sanofi Revenue Proportion by Product in 2024
 Table 48. Sanofi Revenue Proportion by Application in 2024
 Table 49. Sanofi Revenue Proportion by Geographic Area in 2024
 Table 50. Sanofi Pril-series Drugs SWOT Analysis
 Table 51. Sanofi Recent Developments
 Table 52. Novartis Corporation Information
 Table 53. Novartis Description and Major Businesses
 Table 54. Novartis Product Features and Attributes
 Table 55. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Novartis Revenue Proportion by Product in 2024
 Table 57. Novartis Revenue Proportion by Application in 2024
 Table 58. Novartis Revenue Proportion by Geographic Area in 2024
 Table 59. Novartis Pril-series Drugs SWOT Analysis
 Table 60. Novartis Recent Developments
 Table 61. Bristol-Myers Squibb Company Corporation Information
 Table 62. Bristol-Myers Squibb Company Description and Major Businesses
 Table 63. Bristol-Myers Squibb Company Product Features and Attributes
 Table 64. Bristol-Myers Squibb Company Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Bristol-Myers Squibb Company Revenue Proportion by Product in 2024
 Table 66. Bristol-Myers Squibb Company Revenue Proportion by Application in 2024
 Table 67. Bristol-Myers Squibb Company Revenue Proportion by Geographic Area in 2024
 Table 68. Bristol-Myers Squibb Company Pril-series Drugs SWOT Analysis
 Table 69. Bristol-Myers Squibb Company Recent Developments
 Table 70. Pfizer Corporation Information
 Table 71. Pfizer Description and Major Businesses
 Table 72. Pfizer Product Features and Attributes
 Table 73. Pfizer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Pfizer Revenue Proportion by Product in 2024
 Table 75. Pfizer Revenue Proportion by Application in 2024
 Table 76. Pfizer Revenue Proportion by Geographic Area in 2024
 Table 77. Pfizer Pril-series Drugs SWOT Analysis
 Table 78. Pfizer Recent Developments
 Table 79. TAD Pharma Corporation Information
 Table 80. TAD Pharma Description and Major Businesses
 Table 81. TAD Pharma Product Features and Attributes
 Table 82. TAD Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. TAD Pharma Recent Developments
 Table 84. Organon Pharma Corporation Information
 Table 85. Organon Pharma Description and Major Businesses
 Table 86. Organon Pharma Product Features and Attributes
 Table 87. Organon Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Organon Pharma Recent Developments
 Table 89. Huahai Pharmaceutical Corporation Information
 Table 90. Huahai Pharmaceutical Description and Major Businesses
 Table 91. Huahai Pharmaceutical Product Features and Attributes
 Table 92. Huahai Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Huahai Pharmaceutical Recent Developments
 Table 94. Kunshan Rotam Reddy Pharmaceutical Corporation Information
 Table 95. Kunshan Rotam Reddy Pharmaceutical Description and Major Businesses
 Table 96. Kunshan Rotam Reddy Pharmaceutical Product Features and Attributes
 Table 97. Kunshan Rotam Reddy Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Kunshan Rotam Reddy Pharmaceutical Recent Developments
 Table 99. Shenzhen Salubris Pharmaceuticals Corporation Information
 Table 100. Shenzhen Salubris Pharmaceuticals Description and Major Businesses
 Table 101. Shenzhen Salubris Pharmaceuticals Product Features and Attributes
 Table 102. Shenzhen Salubris Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Shenzhen Salubris Pharmaceuticals Recent Developments
 Table 104. Raw Materials Key Suppliers
 Table 105. Distributors List
 Table 106. Market Trends and Market Evolution
 Table 107. Market Drivers and Opportunities
 Table 108. Market Challenges, Risks, and Restraints
 Table 109. Research Programs/Design for This Report
 Table 110. Key Data Information from Secondary Sources
 Table 111. Key Data Information from Primary Sources


List of Figures
 Figure 1. Pril-series Drugs Product Picture
 Figure 2. Global Pril-series Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Enalapril Product Picture
 Figure 4. Lisinopril Product Picture
 Figure 5. Captopril Product Picture
 Figure 6. Ramipril Product Picture
 Figure 7. Perindopril Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Pril-series Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 10. Hospital Pharmaty
 Figure 11. Retail Pharmacy
 Figure 12. Pril-series Drugs Report Years Considered
 Figure 13. Global Pril-series Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 15. Global Pril-series Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 16. Global Pril-series Drugs Revenue Market Share by Region (2020-2031)
 Figure 17. Global Pril-series Drugs Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Enalapril Revenue Market Share by Player in 2024
 Figure 20. Lisinopril Revenue Market Share by Player in 2024
 Figure 21. Captopril Revenue Market Share by Player in 2024
 Figure 22. Ramipril Revenue Market Share by Player in 2024
 Figure 23. Perindopril Revenue Market Share by Player in 2024
 Figure 24. Others Revenue Market Share by Player in 2024
 Figure 25. Global Pril-series Drugs Revenue Market Share by Type (2020-2031)
 Figure 26. Global Pril-series Drugs Revenue Market Share by Application (2020-2031)
 Figure 27. North America Pril-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. North America Top 5 Players Pril-series Drugs Revenue (US$ Million) in 2024
 Figure 29. North America Pril-series Drugs Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Pril-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 31. US Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 32. Canada Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 33. Mexico Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 34. Europe Pril-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 35. Europe Top 5 Players Pril-series Drugs Revenue (US$ Million) in 2024
 Figure 36. Europe Pril-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 37. Europe Pril-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 38. Germany Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 39. France Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 40. U.K. Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 41. Italy Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 42. Russia Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 43. Asia-Pacific Pril-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 44. Asia-Pacific Top 8 Players Pril-series Drugs Revenue (US$ Million) in 2024
 Figure 45. Asia-Pacific Pril-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 46. Asia-Pacific Pril-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 47. Indonesia Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 48. Japan Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. South Korea Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. Australia Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 51. India Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 52. Indonesia Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 53. Vietnam Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 54. Malaysia Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 55. Philippines Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 56. Singapore Pril-series Drugs Revenue (2020-2031) & (US$ Million)
 Figure 57. Central and South America Pril-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 58. Central and South America Top 5 Players Pril-series Drugs Revenue (US$ Million) in 2024
 Figure 59. Central and South America Pril-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 60. Central and South America Pril-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 61. Brazil Pril-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 62. Argentina Pril-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 63. Middle East and Africa Pril-series Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 64. Middle East and Africa Top 5 Players Pril-series Drugs Revenue (US$ Million) in 2024
 Figure 65. South America Pril-series Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Middle East and Africa Pril-series Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 67. GCC Countries Pril-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 68. Israel Pril-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 69. Egypt Pril-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 70. South Africa Pril-series Drugs Revenue (2020-2025) & (US$ Million)
 Figure 71. Pril-series Drugs Industry Chain Mapping
 Figure 72. Channels of Distribution (Direct Vs Distribution)
 Figure 73. Bottom-up and Top-down Approaches for This Report
 Figure 74. Data Triangulation
 Figure 75. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Pril series Drugs API Market Research Report 2024
Global Perindopril tert Butylamine Tablets Market Research Report 2024
Global Enalapril Maleate Market Research Report 2024
Global Antihypertensive Drugs Market Research Report 2024
Global Renin Inhibitors Market Research Report 2025
Global Renin Angiotensin System RAS Inhibitor Market Research Report 2024
Angiotensin Converting Enzyme ACE Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ramipril API Market Research Report 2025
Global Perindopril Erbumine API Market Research Report 2024
Angiotensin Converting Enzyme Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Enalapril Market Research Report 2024
Global Sartan series Drugs Market Research Report 2024
Global Fosinopril Sodium Tablets Market Research Report 2024
Global Enalaprilat Market Research Report 2024
Propranolol Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Propranolol Market
Prilide Antihypertensive Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Enalapril Maleate API Market Research Report 2024
Propranolol Hydrochloride Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Valsartan Hydrochlorothiazide Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Levothyroxine Sodium Tablets Hormone Medication Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-25N19924
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Needle Free Allergy Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24B19783
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Hydrotalcite Antacid Chewable Tablets Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20305
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Dual Orexin Receptor Antagonist Sleeping Pills Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12S20176
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions